You are here: Industry Insights > Market News > Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

biospaceNovember 23, 2017

Tag: NHS , Concordia

Favorites

Concordia International, the Canadian drug company, has overcharged the NHS by more than £100m in the past decade for a life-changing thyroid drug, according to Britain’s competition watchdog.

The Competition and Markets Authority (CMA) said it had provisionally found that Concordia had "abused its dominant position to overcharge the NHS" by hiking the price of liothyronine, used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017.

The regulator said the NHS had spent more than £34m on the drug last year, up from about £600,000 in 2006.

Previous:FDA approves first implanted lens that can be adjusted after cataract surgery to improve vision with

Next:Merck to suspend filing Ebola vaccine for FDA approval until next year

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may like
More>>

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>